BlackRock, Inc. 13D and 13G filings for Verve Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-17 5:40 pm Sale | 2025-03-31 | 13G | Verve Therapeutics, Inc. VERV | BlackRock Inc. BLK | 6,177,751 7.000% | -1,098,596 (-15.10%) | Filing |
| 2025-04-17 09:35 am Purchase | 2025-03-31 | 13G | Verve Therapeutics, Inc. VERV | BlackRock Inc. BLK | 6,177,751 7.000% | 6,177,751 (New Position) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Verve Therapeutics, Inc. VERV | BlackRock Inc. BLK | 7,276,347 8.600% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Verve Therapeutics, Inc. VERV | BlackRock Inc. BLK | 7,276,347 8.600% | 2,840,866 (+64.05%) | Filing |
| 2024-01-29 5:25 pm Purchase | 2023-12-31 | 13G | Verve Therapeutics, Inc. VERV | BlackRock Inc. BLK | 4,435,481 5.600% | 4,435,481 (New Position) | Filing |